Top Markets
Coin of the day
Arch Biopartners Inc. Arch Biopartners Inc.

Arch Biopartners Inc.

ARCH
주식 순위 #25410
Arch Biopartners Inc. is a biotechnology firm dedicated to devising... Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
주가
$0.73393689
마지막 동기화: 2026-08-20
시가총액
$49.86M
변동 (1일)
-8.26%
변동 (1년)
-38.15%
국가
CA
거래 Arch Biopartners Inc. (ARCH)

카테고리

Arch Biopartners Inc. (ARCH)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Arch Biopartners Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Arch Biopartners Inc.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.7087 -
US